Where to buy MOTS-c.

A 2026 sourcing guide for MOTS-c — the 16-amino-acid mitochondrial-derived peptide with the cleanest preclinical biology in the longevity field, the “exercise mimetic” marketing claims that outpace the human data, and the methionine-oxidation storage rules every research buyer should know.

Buying guide9 min read

Key takeaway

MOTS-c is a synthetic 16-amino-acid peptide identical to the natural mitochondrial-derived peptide encoded in mitochondrial DNA. Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. Molecular weight 2174.6 g/mol. Legal to buy as a research reference compound. On November 17, 2026, US research suppliers listed 10 mg vials at $59.99–$116.00. The two specific traps: pre-reconstituted solution shipped without cold chain (the methionines oxidize), and vendors making clinical exercise-mimetic claims that significantly outpace the human evidence.

At a glance

Article typeBuying guide
Main guideMOTS-c: complete guide
Regulatory statusNot FDA-approved“Regulatory: not FDA-approved” (MOTS-c: complete guide)
ClassCell metabolism & aging
Studies cited6 in this article · 31 across 8 articles on MOTS-c
ProductMOTS-c product page

MOTS-c is among the most scientifically characterized mitochondrial-derived peptides available as a research reference compound — a 16-amino-acid molecule encoded in the mitochondrial genome, with broad preclinical literature behind it. The gap that matters: as of mid-2026, zero human randomized trials of synthetic MOTS-c have been published. Where to buy MOTS-c in 2026 means a research-supply vendor, full stop. The three identity-verification questions that matter: does the sequence match, does the mass match, and is the lot fresh enough that oxidation has not compromised the reference material?

Get new research first

Research updates
Citation-anchored summaries New-batch COA alerts Unsubscribe anytime

One short email when new peptide research drops or a new lab-verified batch lands — written from primary sources, no filler.

The 60-second answer: Buy lyophilized (freeze-dried) powder from a research-supply vendor. Get a third-party CoA showing HPLC purity ≥98%, mass-spec at [M+H]+ 2175.6, and explicit methionine-sulfoxide disclosure. Standard 16-mer only — ignore “MOTS-c Plus” or “Stabilized MOTS-c” variants. On November 17, 2026, US research suppliers listed 10 mg vials at $59.99–$116.00.

Your three channels, and what each one gets you

MOTS-c is not an approved drug. So how do you actually buy it? Three channels exist:

  • Doctor’s prescription: Not available. MOTS-c isn’t an FDA-approved drug.
  • Compounding pharmacy: FDA lists MOTS-c among compounding substances that may present significant safety risks (nomination withdrawn). In July 2026, FDA proposed that it not be included on the 503A Bulks List. Most compounding pharmacies won’t touch it.
  • Research-supply vendor: The standard channel. Lyophilized powder under Research Use Only labeling. No prescription.

What the research-supply channel provides: Lyophilized reference compound under Research Use Only labeling. No FDA-regulated batch testing or physician oversight. No published human interventional data — preclinical characterization is rodent-model-only as of mid-2026.

What you’re actually buying

MOTS-c is a 16-residue peptide. The full sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg.

Here’s what makes MOTS-c unusual. Unlike most research peptides, synthetic MOTS-c is chemically identical to a peptide the human body produces. It’s encoded inside mitochondrial DNA. It circulates in blood. Its concentration drops measurably with age. The discovery paper came from Changhan Lee and Pinchas Cohen’s lab at USC (Lee et al., 2015).

That endogenous origin matters for sourcing. The 16-mer sequence is locked in. It’s not subject to vendor reinterpretation. A 2024 iScience paper identified a protein called CK2 as MOTS-c’s direct binding partner in muscle. A natural variant (K14Q) reduces that binding and is linked to higher sarcopenia and diabetes risk (Kumagai et al., 2024). The sequence is real biology, not marketing.

“

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.

— Lee et al., Cell Metabolism, 2015 (discovery paper, mouse model)

The four checks that matter for MOTS-c

The standard eight vendor criteria apply. Four are sharper here.

1. Sequence verification: the 16-mer matters

MOTS-c is 16 amino acids encoded in the human mitochondrial 12S rRNA. The sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. A research-grade CoA should list it in full.

Cross-reference against the original 2015 Cell Metabolism paper or the UniProt database entry. Both are publicly accessible. If a vendor sells “mitochondrial peptide” with no sequence, or a partial sequence, or a modified variant, the material does not correspond to the molecule in the published literature.

2. The exercise-mimetic claim outpaces the human evidence

“Exercise mimetic” is the most heavily used MOTS-c marketing line. The gap between what that phrase implies and what’s been demonstrated in humans is the second-biggest red flag.

The mechanism is real in rodents. Exogenous MOTS-c improves exercise capacity and metabolic markers in young and aged mice. Acute high-intensity exercise also raises plasma MOTS-c in human subjects (Woodhead & Merry, 2021).

What doesn’t exist: a published randomized human trial showing synthetic MOTS-c produces the outcomes the marketing implies. Vendor copy calling it a “workout replacement” or “adipose-reduction peptide” is selling rodent data to human buyers.

3. Pricing that reflects the synthesis

MOTS-c is 16 residues, no modifications, but two methionines, two tryptophans, and three arginines make synthesis slightly more complex than simpler 16-mers. On November 17, 2026, US research suppliers listed 10 mg vials at $59.99–$116.00.

A price far below the rest of the market? Ask why. The HPLC purification step is what separates crude MOTS-c (with deletion impurities and oxidation products) from a clean reference compound. Above $25 per mg, you’re paying retail markup.

4. Storage: methionine oxidation is the killer

Two methionines (positions 1 and 6) get oxidized when air hits them. That’s the single most important storage consideration for MOTS-c. Controlled cold-chain shipping matters more here than for most simpler peptides.

Lyophilized MOTS-c, sealed and stored at −20°C, is stable for years. Reconstituted MOTS-c at 2–8°C is rated for 30 days. Repeated freeze-thaw cycles speed up oxidation. A credible CoA quantifies methionine sulfoxide as a separate impurity, not just total purity. Pre-reconstituted product without cold chain is the highest-risk format.

MOTS-c

Mitochondrial-derived 16 aa 12S rRNA origin

The standard 16-mer sequence cited across the 2015 discovery paper in Cell Metabolism and the 2024 CK2-binding study in iScience. Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg, observed mass [M+H]+ 2175.6, ≥99% HPLC purity, third-party CoA with methionine oxidation disclosure on every lot.

View MOTS-c

What you should pay in 2026

MOTS-c costs more per mg than the cheapest research peptides because of the two methionines and three arginines. We checked US research supplier product pages on November 17, 2026. Listed single-vial prices, before shipping and codes:

  • 10 mg vial: $59.99–$116.00 ($6.00–$11.60 per mg).
  • Larger vials: one supplier listed 40 mg at $45.00 and another 50 mg at $189.99 ($1.13–$3.80 per mg). Best per-mg economics.
  • Multi-vial discounts: some suppliers discount larger orders.

The full table, with each supplier and source, is on our peptide price list.

A price far below the rest of the market? Ask why. The cheap end usually means skipped HPLC purification or expired stock with elevated oxidation. Above $25 per mg, you’re paying retail markup.

MOTS-c is not FDA-approved. Not EMA-approved either. It’s sold legally as a Research Use Only reference compound under 21 CFR § 809.10(b)(9).

MOTS-c was nominated for 503A compounding, and the nomination was withdrawn. FDA lists it among compounding substances that may present significant safety risks. At the July 23, 2026 Pharmacy Compounding Advisory Committee meeting, FDA proposed that MOTS-c (free base) and MOTS-c acetate not be included on the 503A Bulks List.

The WADA status is the line to watch. MOTS-c is not currently listed on the WADA Prohibited List. But WADA has flagged mitochondrial-derived peptides as a class of emerging interest. The 2024 K14Q variant paper documented muscle effects in humans — exactly the kind of finding anti-doping agencies track. For competing athletes, assume MOTS-c could move onto the Prohibited List on short notice.

Red flags specific to MOTS-c

  • Pre-reconstituted MOTS-c shipped without cold chain. The methionines oxidize on air exposure. Pre-mixed product at ambient temperature has a much shorter usable window than lyophilized powder — and oxidation damage is not detectable without analytical testing.
  • “Exercise mimetic” or “workout replacement” copy. Real in mice. Unproven in humans. Vendor copy that frames MOTS-c as a validated human therapy is selling rodent data.
  • No methionine oxidation disclosure on the CoA. A flat “≥98% purity” figure does not indicate whether the remaining impurity is oxidized methionine or another species. A credible CoA quantifies methionine sulfoxide as a separate impurity.
  • Capsules, sublingual sprays, or transdermal patches. Not validated in published research. The lyophilized powder form reconstituted in aqueous solution is the format used across the peer-reviewed literature.
  • Mass-spec not matching 2175.6 [M+H]+. A mass at 2191.6 ([M+H]+ + 16 Da) means oxidation has already happened.
  • Internal QC only, no third-party ISO 17025 lab. An outside accredited lab on the report is the standard.
  • “MOTS-c Plus,” “Stabilized,” or “MOTS-c Acetate” variants. The standard 16-mer is what the published biology applies to. Branded variants are marketing.
Figure 1

MOTS-c published evidence by tier.

The MOTS-c preclinical literature is broad and high-quality across multiple disease models. The translational ladder above it is essentially empty — no PubMed-indexed RCTs of exogenous MOTS-c administration in humans have been published. Researchers should set evidence-tier expectations accordingly.

0 papers 10 25 40+ papers In-vitro / cell models Dozens — CK2, AMPK, Bcl-2, MAVS, USP7/LARS1 Rodent models 25+ studies, metabolic / muscle / liver / cancer Observational human Endogenous plasma MOTS-c, K14Q variant carriers Interventional human (RCTs) 0 published PubMed-indexed RCTs Authorship concentration Large fraction from USC Cohen lab Mechanism reviews (2020+) Frontiers in Endocrinology, GeroScience, BBA FDA / WADA status Not FDA-approved; not currently WADA-listed

Source: aggregate counts from the 2020 GeroScience review (Kim et al., 2020), 2023 Frontiers in Endocrinology review (Zheng et al., 2023), and PubMed retrievals 2015–2026.

MOTS-c

10 mg ≥99% pure Lyophilized

Standard 16-mer mitochondrial-derived peptide. The same reference compound used across the 2024 CK2 binding study and the broader USC Cohen lab MOTS-c literature. COA with HPLC trace, mass-spec, and methionine oxidation disclosure ships with every order.

Learn more

Frequently asked questions

Is MOTS-c legal to buy in the USA?

Yes, as a research reference compound. Not FDA-approved. FDA has proposed against adding it to the 503A Bulks List. Not on the WADA Prohibited List (yet). Selling for human consumption is illegal. Buying as research material is not.

How much should research-grade MOTS-c cost?

On November 17, 2026, US research suppliers listed MOTS-c at $59.99–$116.00 per 10 mg vial, or $1.13–$11.60 per mg across sizes. Far below this range, lower purity or oxidized material is more likely. Far above it, the premium reflects retail markup rather than synthesis cost. Our peptide price list has the full table.

Is the “exercise mimetic” claim real?

Real in mice. Unproven in humans. The 2015 discovery paper and 2021 BBA review document the rodent effects. Acute exercise also raises endogenous MOTS-c in human blood. But no human trial of synthetic MOTS-c administration has been published. The mechanism is genuine; the human data is not yet there.

How does MOTS-c compare to other mitochondrial peptides?

MOTS-c and humanin are the two best-characterized mitochondrial-derived peptides, both from the USC Cohen lab. SS-31 (elamipretide) is different: a synthetic 4-residue peptide with completed Phase III trials (some negative, some positive). MOTS-c has cleaner endogenous biology than SS-31, but no human trial record. SS-31 has a thinner mechanism story but real human data. See SS-31 vs MOTS-c.

What should a MOTS-c Certificate of Analysis show?

The full 16-aa sequence. HPLC purity ≥98% with a chromatogram. Mass-spec at [M+H]+ 2175.6. Water content 2–8% via Karl Fischer titration (a chemistry test for trace water). Counterion content (usually trifluoroacetate). And critically: explicit methionine sulfoxide disclosure as a separate impurity. An ISO 17025-accredited lab on the report.

How should MOTS-c be stored?

The methionines oxidize. That’s the storage consideration unique to MOTS-c. Lyophilized at −20°C, sealed: stable for years. Reconstituted at 2–8°C: rated for 30 days. Avoid repeated freeze-thaw cycles. Each cycle speeds up oxidation. Air exposure above refrigerator temperature destroys it faster than the typical peptide.

What to know now

  • 16-aa sequence, MW 2174.6, [M+H]+ 2175.6. The identity figures a research-grade CoA should report.
  • $59.99–$116.00 per 10 mg vial on November 17, 2026. Slightly above the cheapest peptides because of two methionines and three arginines.
  • Exercise-mimetic claim: real in mice, unproven in humans. Zero published human trials.
  • Methionine oxidation is the killer. CoA must quantify it. Pre-reconstituted product without cold chain is the highest-risk format.
  • Standard 16-mer only. “Plus,” “Stabilized,” “Acetate” variants are marketing.
  • WADA: not yet listed, but watch the space. Mitochondrial-derived peptides are an emerging area of anti-doping interest.

What we’re watching

The big MOTS-c development to track: whether a Phase I or Phase II controlled human trial ever publishes. Ten years into the literature, the human interventional evidence is still zero RCTs. The 2024 iScience CK2 paper and the K14Q variant work point to sarcopenia and type 2 diabetes as the most plausible first clinical indications. Separately, watch the WADA Prohibited List for any 2027 update that adds mitochondrial-derived peptides as a class. The anti-doping signal has been gathering for years. An explicit listing on short notice is the scenario research buyers should plan for.

Also in the library

Sources: Lee 2015, Cell Metabolism; Kumagai 2024, iScience; Kumagai 2021, American Journal of Physiology-Endocrinology and Metabolism; Woodhead 2021, Biochimica et Biophysica Acta (BBA) - General Subjects; Zheng 2023, Frontiers in Endocrinology; Kim 2020, GeroScience; International Organization for Standardization 2017; World Anti-Doping Agency 2026, The World Anti-Doping Code International Standard — Prohibited List. All 8 citations

Back to the research library

References

  1. Lee, C., Zeng, J., Drew, B. G., Sallam, T., Martin-Montalvo, A., Wan, J., Kim, S.-J., Mehta, H., Hevener, A. L., de Cabo, R., & Cohen, P. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454. https://doi.org/10.1016/j.cmet.2015.02.009
  2. Kumagai, H., Kim, S.-J., Miller, B., Natsume, T., Wan, J., Kumagai, M. E., Ramirez, R., Lee, S. H., Sato, A., Mehta, H. H., Yen, K., & Cohen, P. (2024). MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience, 27(11), 111212. https://doi.org/10.1016/j.isci.2024.111212
  3. Kumagai, H., Coelho, A. R., Wan, J., Mehta, H. H., Yen, K., Huang, A., Zempo, H., Fuku, N., Maeda, S., Oliveira, P. J., Cohen, P., & Kim, S.-J. (2021). MOTS-c reduces myostatin and muscle atrophy signaling. American Journal of Physiology-Endocrinology and Metabolism, 320(4), E680–E690. https://doi.org/10.1152/ajpendo.00275.2020
  4. Woodhead, J. S. T., & Merry, T. L. (2021). Mitochondrial-derived peptides and exercise. Biochimica et Biophysica Acta (BBA) - General Subjects, 1865(12), 130011. https://doi.org/10.1016/j.bbagen.2021.130011
  5. Zheng, Y., Wei, Z., & Wang, T. (2023). MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology, 14, 1120533. https://doi.org/10.3389/fendo.2023.1120533
  6. Kim, S.-J., Miller, B., Kumagai, H., Silverstein, A. R., Flores, M., & Yen, K. (2020). Mitochondrial-derived peptides in aging and age-related diseases. GeroScience, 43(3), 1113–1121. https://doi.org/10.1007/s11357-020-00262-5
  7. International Organization for Standardization. (2017). ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html
  8. World Anti-Doping Agency. (2026). The World Anti-Doping Code International Standard — Prohibited List. https://www.wada-ama.org/en/prohibited-list